Therapeutic implications of the use of cardiac markers in acute coronary syndromes

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 59, Issue 230, 1999, Pages 43-49

  Lindahl, Bertil ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute coronary syndromes; Cardiac markers; Treatment; Troponin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TROPONIN T; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ELECTROCARDIOGRAPHY; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; ST SEGMENT ELEVATION; ACUTE DISEASE; BLOOD; CORONARY ARTERY DISEASE; REVIEW;

ACUTE DISEASE; BIOLOGICAL MARKERS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HUMANS; RISK ASSESSMENT; TROPONIN T;

EID: 0033038126     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519909168326     Document Type: Conference Paper

References (26)

1. Braunwald E. Unstable angina: an etiologic approach to management. Circulation 1998;98(21):2219-22.
2. de Boer MJ, Hoorntje JC, Ottervanger JP, Reiffers S, Suryapranata H, Zijlstra F. Immediate coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: left ventricular ejection fraction, hospital mortality and reinfarction. J Am Coll Cardiol 1994;23(5):1004-8.
3. Grines CL, Browne KF, Marco MD, et al. A comparison of immediate angioplasty with thrombolytic theraphy for acute myocardial infarction. N Engl J Med 1993;328(10):673-9.
4. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997;336(23):1621-8.
5. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996;335:1331-41.
6. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation 1996;94(6):1291-7.
7. Ramanathan K, Stewart JT, Theroux P, French JK, White HD. Admission troponin T level may predict 90 minute TIMI flow after thrombolysis. Circulation 97; 96: 1270 (abstract).
8. Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, Siegbahn A, Swahn E, Venge P, Wallentin L.. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction - a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II) J Am Coll Cardiol 1999;33:627-33.
9. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343(8893):311-22.
10. Stenestrand U, Lindahl B, Wallentin L. Difficulties in the diagnosis and treatment of acute myocardial infarction in patients with left bundle-branch block at admission. Eur Heart J 1998;19(Abstract supplement): 631.
11. Lindahl B, Venge P, Wallentin L. Early diagnosis and exclusion of acute myocardial infarction by biochemical monitoring. Coronary Artery Disease 1995; 6: 321-28.
12. Langer A, Goodman S, Topol E, et al. Late assessment of thrombolytic Efficacy (LATE) study: Prognosis in patients with non-Q wave myocardial infarction. J Am Coll Cardiol 1996;27:1327-32.
13. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation 1996;93:1651-57.
14. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
15. Terres W, Kummel P, Sudrow A, Reuter H, Meinertz T, Hamm CW. Enhanced coagulation activation in troponin T-positive unstable angina pectoris. Am Heart J 1998; 135: 281-6.
16. Jurlander B, Molani MA, Balu D, Ellis AK. Serum troponin T levels predicts coronary angigraphic findings in patients with unstable angina. Circulation 1995;92:I-679 (Abstract).
17. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998;79(3):491-4.
18. Fragmin during instability in coronary artery disease (FRISC) study group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996;347:561-68.
19. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long term antithrombotic protection. J Am Coll Cardiol 1997;29:43-8.
20. Hamm CW, Heeschen C, Goldmann B, et al. Troponin T predicts the benefit of abciximab in patients with unstable angina in the CAPTURE study. Eur Heart J 1998;19(Abstract supplement): 631.
21. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995;26(7):1643-50.
22. Boden WE, RA OR, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338(25):1785-92.
23. Wallentin L, Husted S, Kontny F, Swahn E. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). Am J Cardiol 1997;80(5A):61E-63E.
24. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342(8875):821-8.
25. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669-77.
26. Rao AC, Collinson PO, Canepa-Anson R, Joseph SP. Troponin T measurement after myocardial infarction can identify left ventricular ejection of less than 40%. Heart 1998;80(3):223-5.